Literature DB >> 25678597

HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer.

Haifeng Zhu1, Zuzana Berkova1, Rohit Mathur1, Lalit Sehgal1, Tamer Khashab1, Rong-Hua Tao1, Xue Ao1, Lei Feng2, Anita L Sabichi3, Boris Blechacz4, Asif Rashid5, Felipe Samaniego6.   

Abstract

UNLABELLED: Hepatocellular carcinomas (HCC) show resistance to chemotherapy and have blunt response to apoptotic stimuli. HCC cell lines express low levels of the Fas death receptor and are resistant to FasL stimulation, whereas immortalized hepatocytes are sensitive. The variable Fas transcript levels and consistently low Fas protein in HCC cells suggest posttranscriptional regulation of Fas expression. The 3'-untranslated region (UTR) of Fas mRNA was found to interact with the ribonucleoprotein Human Antigen R (HuR) to block mRNA translation. Silencing of HuR in HCC cells increased the levels of cell surface Fas and sensitized HCC cells to FasL. Two AU-rich domains within the 3'-UTR of Fas mRNA were identified as putative HuR-binding sites and were found to mediate the translational regulation in reporter assay. Hydrodynamic transfection of HuR plasmid into mice induced downregulation of Fas expression in livers and established functional resistance to the killing effects of Fas agonist. Human HCC tumor tissues showed significantly higher overall and cytoplasmic HuR staining compared with normal liver tissues, and the high HuR staining score correlated with worse survival of patients with early-stage HCC. Combined, the protumorigenic ribonucleoprotein HuR blocks the translation of Fas mRNA and effectively prevents Fas-mediated apoptosis in HCC, suggesting that targeting HuR would sensitize cells to apoptotic stimuli and reverse tumorigenic properties. IMPLICATIONS: Demonstrating how death receptor signaling pathways are altered during progression of HCC will enable the development of better methods to restore this potent apoptosis mechanism. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25678597     DOI: 10.1158/1541-7786.MCR-14-0241

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  21 in total

1.  HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.

Authors:  Carmella Romeo; Matthew C Weber; Mahsa Zarei; Danielle DeCicco; Saswati N Chand; Angie D Lobo; Jordan M Winter; Janet A Sawicki; Jonathan N Sachs; Nicole Meisner-Kober; Charles J Yeo; Rajanikanth Vadigepalli; Mark L Tykocinski; Jonathan R Brody
Journal:  Mol Cancer Res       Date:  2016-04-06       Impact factor: 5.852

Review 2.  Apoptosis in liver carcinogenesis and chemotherapy.

Authors:  Joaquim Moreno-Càceres; Isabel Fabregat
Journal:  Hepat Oncol       Date:  2015-11-11

Review 3.  Neddylation, a novel paradigm in liver cancer.

Authors:  Teresa Cardoso Delgado; Lúcia Barbier-Torres; Imanol Zubiete-Franco; Fernando Lopitz-Otsoa; Marta Varela-Rey; David Fernández-Ramos; María-Luz Martínez-Chantar
Journal:  Transl Gastroenterol Hepatol       Date:  2018-06-30

4.  The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.

Authors:  F F Blanco; M Jimbo; J Wulfkuhle; I Gallagher; J Deng; L Enyenihi; N Meisner-Kober; E Londin; I Rigoutsos; J A Sawicki; M V Risbud; A K Witkiewicz; P A McCue; W Jiang; H Rui; C J Yeo; E Petricoin; J M Winter; J R Brody
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

Review 5.  Understanding and targeting the disease-related RNA binding protein human antigen R (HuR).

Authors:  Christopher W Schultz; Ranjan Preet; Teena Dhir; Dan A Dixon; Jonathan R Brody
Journal:  Wiley Interdiscip Rev RNA       Date:  2020-01-23       Impact factor: 9.957

Review 6.  Cancer the'RBP'eutics-RNA-binding proteins as therapeutic targets for cancer.

Authors:  Shakur Mohibi; Xinbin Chen; Jin Zhang
Journal:  Pharmacol Ther       Date:  2019-07-11       Impact factor: 12.310

7.  An Evolutionarily Conserved AU-Rich Element in the 3' Untranslated Region of a Transcript Misannotated as a Long Noncoding RNA Regulates RNA Stability.

Authors:  Emily A Dangelmaier; Xiao Ling Li; Corrine Corrina R Hartford; Julianna C King; Meira S Zibitt; Raj Chari; Ioannis Grammatikakis; Ashish Lal
Journal:  Mol Cell Biol       Date:  2022-03-11       Impact factor: 5.069

8.  Essential Roles of RNA-binding Protein HuR in Activation of Hepatic Stellate Cells Induced by Transforming Growth Factor-β1.

Authors:  Jingjing Ge; Na Chang; Zhongxin Zhao; Lei Tian; Xianghui Duan; Lin Yang; Liying Li
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

9.  LncRNA MT1JP functions as a tumor suppressor by interacting with TIAR to modulate the p53 pathway.

Authors:  Lihui Liu; Haiyan Yue; Qinghua Liu; Jiao Yuan; Jing Li; Guifeng Wei; Xiaomin Chen; Youyong Lu; Mingzhou Guo; Jianjun Luo; Runsheng Chen
Journal:  Oncotarget       Date:  2016-03-29

10.  Murine double minute 2, a potential p53-independent regulator of liver cancer metastasis.

Authors:  Atul Ranjan; Kaustav Bera; Tomoo Iwakuma
Journal:  Hepatoma Res       Date:  2016-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.